Halozyme Therapeutics, Inc. - Common Stock (HALO)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Mar 29, 2026Investment Snapshot
- Trading 799% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- Strong ROE of 1,219.9% with 48.2% net margin
- Revenue growing at 38% annually
Halozyme Therapeutics, Inc. - Common Stock (HALO) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $7.3 billion . Key value metrics: P/E ratio 12.2, P/B ratio 149.00, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Halozyme Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary
Halozyme Therapeutics, Inc. - Common Stock (HALO) is currently trading 799% above its Graham Number of $6.85, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 12.2x.
On financial health, HALO shows a moderate Piotroski F-Score of 5/9, and strong return on equity of 1,219.9% (sector average: -19.8%), and high leverage with a debt-to-equity ratio of 43.89.
StockPik's composite Value Score for HALO is 64/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
HALO reports a high gross margin of 83.9% (sector average: 33.5%) and a strong operating margin of 58.7%.
HALO shows revenue growing at 38% year-over-year, with earnings declining at 29%.